Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

Malmstrom, Annika; Gronberg, Bjorn; Marosi, Christine; Stupp, Roger; Frappaz, Didier; Schultz, Henrik; Abacioglu, Ufuk; Tavelin, Bjorn; Lhermitte, Benoit; Hegi, Monika; Rosell, Johan; Henriksson, Roger

doi:10.1016/s1470-2045(12)70265-6

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

Malmstrom A., Gronberg B. H., Marosi C., Stupp R., Frappaz D., Schultz H., ...Daha Fazla

LANCET ONCOLOGY, cilt.13, sa.9, ss.916-926, 2012 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 13 Sayı: 9
Basım Tarihi: 2012
Doi Numarası: 10.1016/s1470-2045(12)70265-6
Dergi Adı: LANCET ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.916-926
Marmara Üniversitesi Adresli: Evet

Özet

Background Most patients with glioblastoma are older than 60 years, but treatment guidelines are based on trials in patients aged only up to 70 years. We did a randomised trial to assess the optimum palliative treatment in patients aged 60 years and older with glioblastoma.